SCHEMBL4071602

SCHEMBL4071602

CC[C@H]1CC(=O)C[C@H](CC)N1C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CETP P11597 2/20 0.44
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
NR1H2 P55055 1/20 0.37
PREP P48147 3/20 0.36
ABCB1 P08183 1/20 0.36
GLA P06280 1/20 0.36
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CTSK P43235 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
HSD11B1 P28845 1/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL759308 1.00 CETP (0.44) CETPCHRM2CHRM1CHRM3NR1H2
SCHEMBL4038626 1.00 CETP (0.44) CETPCHRM2CHRM1CHRM3NR1H2
SCHEMBL759059 1.00 CETP (0.44) CETPCHRM2CHRM1CHRM3NR1H2
SCHEMBL14319923 1.00 CETP (0.44) CETPCHRM2CHRM1CHRM3NR1H2
SCHEMBL3942588 0.91 CETP (0.42) CETPCHRM2CHRM1CHRM3NR1H2
SCHEMBL14311414 0.91 CETP (0.42) CETPCHRM2CHRM1CHRM3NR1H2
SCHEMBL13609053 0.91 CETP (0.42) CETPCHRM2CHRM1CHRM3NR1H2
SCHEMBL24212059 0.91 CHRM2 (0.40) CETPCHRM2CHRM1CHRM3NR1H2
SCHEMBL13845952 0.91 CHRM2 (0.40) CETPCHRM2CHRM1CHRM3NR1H2
SCHEMBL21064056 0.91 CHRM2 (0.40) CETPCHRM2CHRM1CHRM3NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049517-B1 AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS NOVARTIS AG (CH) 2013-11-27 EP disclosed
US-20090286790-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-11-19 US disclosed
US-20090286790-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-11-19 US disclosed
US-20090286790-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-11-19 US disclosed
WO-2008009435-A1 AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS NOVARTIS AG (CH) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286790-A1 ORGANIC COMPOUNDS CETP, NPC1, CES1 CETP 1/4885CHRM2 1620/4885CHRM1 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.